Navigation Links
Oppenheimer's 24th Annual Healthcare Conference Provides Investor Access To Emerging And Established Companies

NEW YORK, Dec. 13, 2013 /PRNewswire/ -- Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings Inc., is  pleased to announce the completion of its 24th Annual Healthcare Conference, which took place on December 10 – 11, 2013, in New York.   More than 130 public and private companies, representing  all major sectors of the healthcare industry including bio & specialty pharmaceuticals; biotechnology; medical devices; healthcare facilities; life science tools and diagnostics; healthcare information technology and distribution, and healthcare providers and servicers participated in this two-day program.  The conference attracted more than 700 attendees.

The Oppenheimer Healthcare Conference consisted of a mix of formal company presentations and one-on-one meetings.  

The keynote speaker Ted Kennedy, Jr., President & Co-Founder, The Marwood Group, provided insights into the latest developments in Washington , D.C. and discussed the regulatory environment as well as the headwinds and tailwinds across many sectors of the healthcare industry.  

"This is Oppenheimer's 24th consecutive year of producing this conference, and it demonstrates our long-standing commitment to the healthcare industry. We are pleased to be able to continue to offer this conference for investors to meet with emerging and established healthcare companies as they evaluate the opportunities in the sector over the next 12-18 months," said Erica Moffett, Managing Director and Associate Director of Research.

Panels included "How Emerging Biopharma Companies Successfully Execute Their First Commercial Launch," and "China Healthcare Holds Opportunities for Global Investors and Healthcare Companies: How to Capture Them?"  Other panels looked at the growing use of big data in healthcare and the evolving healthcare model which included CEOs of two of the leading hospital systems in the U.S. discussing  the significant payment and care delivery changes ahead.

In the current environment of healthcare reform, increased regulation and rising costs, the conference offered investors a unique opportunity to meet with CEOs and CFOs of healthcare companies and learn first hand what issues and trends will drive the sector in 2014 and beyond in the  U.S., Europe and China.  

"The Oppenheimer Healthcare Conference has been an excellent forum to highlight our plans for launching OTREXUP following the NDA approval in October," said Paul Wotton, President and CEO of Antares Pharma.

Oppenheimer provides research coverage of more than 110 companies in the healthcare sector and is an active underwriter of healthcare stocks.

Oppenheimer & Co. Inc., a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), provides a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Certain statements in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.

SOURCE Oppenheimer & Co. Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Med Ad News Honors Healthcare Communication Agencies at 23rd Annual Manny Awards
4. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
5. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
6. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
7. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
8. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
9. Henry Schein To Present At The Deutsche Bank 37th Annual Health Care Conference
10. Stereotaxis Epoch™ Solutions Momentum Drives Strong Presence at the Heart Rhythm Society (HRS) Annual Meeting
11. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
Post Your Comments:
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: ... that developed an innovative way to use nonlinear optical ... delivery of new drugs. ... Dermatology Conference will show how researchers from BioPharmX and ... Medical School used a suite of imaging techniques in ...
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
Breaking Medicine News(10 mins):